Waters Corporation Beats Q2 Guidance on Strong Organic Growth and Acquisition Performance

The analytical instruments maker posted $1.645 billion in total revenue, exceeding expectations with 9% constant-currency organic growth.

WAT · 2026-08-04 · MarginX

Revenue Surpasses Guidance Range

Waters Corporation (NYSE: WAT) announced second quarter 2026 financial results on August 4, reporting total revenue of $1.645 billion that exceeded the high end of its guidance range. The Milford, Massachusetts-based analytical instruments manufacturer saw broad-based outperformance across both its core operations and recently acquired businesses.

Organic Growth Accelerates

The company's organic revenue reached $828 million, representing 7% growth on a reported basis and 9% growth in constant currency. The strong organic performance suggests resilient demand for Waters' laboratory instruments and consumables across its end markets, which typically include pharmaceutical, life sciences, and industrial applications.

The results indicate that both the company's legacy operations and its M&A strategy are contributing to top-line expansion, with acquired businesses complementing the organic growth trajectory.

Market Context

With a market capitalization of approximately $37 billion and shares closing at $374.74 ahead of the announcement, Waters remains one of the larger players in the analytical instruments sector. The company is scheduled to host its Q2 2026 earnings call later today, according to MarginX data, where management is expected to provide additional details on segment performance and forward guidance.

Recent insider activity has been limited to routine equity awards and tax withholdings, MarginX data shows. Company executives Heather Knight and Wei Jiang received stock awards of 63.03 and 67.42 shares respectively, while Robert L. Carpio III had 189 shares withheld for tax purposes.

Looking Ahead

Investors will be monitoring the earnings call for commentary on demand trends, particularly in key pharmaceutical and biotech end markets, as well as updates on integration progress for recent acquisitions. The company's performance comes as market participants await the Federal Reserve's September 16 policy decision, which could influence capital spending patterns among Waters' customer base.

This article was generated by MarginX from public news on 2026-08-04. It is not investment advice.

Go deeper on WAT — scores, valuation multiples, filings and earnings-call search on MarginX.